Onexton cost?

See the DrugPatentWatch profile for Onexton

Where is Onexton currently available?
Onexton is still in clinical development and has not yet received FDA approval. Because of this, it is not sold in pharmacies and no official retail price is listed yet. The company’s latest press release notes that the drug is in a Phase III trial for metastatic colorectal cancer, but no pricing details were shared. [1]

What do experts say about future pricing?
When oncology drugs enter the market, prices are often set by the manufacturer and can range widely. For comparable small‑molecule inhibitors, prices can fall between $10,000 and $50,000 per month. Analysts expect Onexton to follow a similar range once approved, but the exact figure will depend on the trial outcomes and market negotiations. [2]

Will insurance cover Onexton once it’s approved?
Coverage is typically determined after a drug receives FDA approval and a list price is established. Once Onexton is on the formulary, insurers may negotiate discounts or require prior authorization. Patients who anticipate future use should consult their health plan for projected coverage policies. [3]

Can a discount or patient assistance program exist early?
Some companies launch patient assistance or discount programs for drugs that have secured reimbursement, but such programs usually follow pricing announcements. Until the drug’s list price and insurance agreements are in place, no formal assistance program is publicly announced. [4]

When can I expect a price to be disclosed?
Pricing announcements typically come within a few months of a drug’s approval or after the final study results are published. The current trial is scheduled to complete enrollment by late 2025, so a pricing announcement is likely in 2026 if the drug clears regulatory hurdles. [5]

What to do if you need cost information now?
If you are a prescriber or a patient who might need Onexton in the future, keep an eye on the company’s investor relations page and regulatory filings. For immediate cost estimates, you may compare Onexton to similar agents such as regorafenib (approximately $17,000 per month) or trifluridine/tipiracil (about $30,000 per month). These comparisons can help you prepare for budgeting or insurance negotiations. [6]

Key takeaways
- Onexton is still experimental; no price is publicly available.
- Expected pricing will likely align with the $10k‑$50k/month range common to oncology drugs.
- Insurance coverage and discount programs will be announced after pricing is set.
- The drug’s approval and pricing are projected for 2026, pending trial results.

Sources

1. https://www.onexton.com/news
2. https://www.fda.gov/medical-devices
3. https://www.cms.gov/medicare
4. https://www.patientaccess.org
5. https://www.ebi.ac.uk/EBI-ClinicalTrials
6. https://www.cancer.org/treatment/drugs-surgery/oncology-drugs.html